Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 139

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY...

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic...

Psyence Group Announces Closing of Second Tranche of Private Placement and...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets...

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for...

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Vital 2023: Informational Session and Q&A

Psychedelic Health – New course launches to bridge the psychedelic education...

Vice – How to Microdose Drugs Based on What You’re Using

Load more

EDITOR PICKS

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©